However, treatment with anti–PD-1 plus anti–CTLA-4, blocking 2 immune checkpoints, improved PKD outcomes in adult-onset ADPKD mice; neither monotherapy altered PKD severity. This evidence concerns the gene PDCD1 and autosomal dominant polycystic kidney disease.